Metronidazole Braun (Metronidazole)

Metronidazole is a nitroimidazole antibiotic used to manage infections caused by anaerobic bacteria and certain protozoa.

• Anaerobic bacterial infections: effective in eliminating susceptible anaerobes, reducing infection severity.
• Clostridioides difficile infection: helps eradicate toxin‑producing C. difficile strains in mild to moderate cases.
• Bacterial vaginosis: restores normal vaginal flora by targeting anaerobic organisms responsible for the condition.
• Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission.
• Amebic liver abscess: treats Entamoeba histolytica infection of the liver, aiding resolution of abscesses.

• Metronidazole enters susceptible anaerobic microorganisms and is reduced by intracellular electron transport proteins to generate nitro radical anions. These reactive intermediates bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, ultimately leading to cell death. The drug’s selective activation in low‑oxygen environments accounts for its activity against anaerobic bacteria and protozoa.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset or queasiness.
• Metallic taste: transient metallic sensation in the mouth.
• Headache: mild to moderate head pain.
• Diarrhea: loose stools, usually self‑limiting.
• Skin rash: mild erythema or itching.

Serious or Rare Side Effects

• Seizures: neurological events requiring immediate attention.
• Peripheral neuropathy: tingling or numbness in extremities.
• Severe allergic reaction: anaphylaxis, swelling, or difficulty breathing.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Blood dyscrasias: neutropenia, thrombocytopenia, or anemia.

When using Metronidazole Braun, clinicians should consider several precautionary measures to ensure safe administration.

• Pregnancy: avoid use unless benefits outweigh risks, as safety data are limited.
• Liver impairment: adjust therapy and monitor hepatic function in patients with liver disease.
• Alcohol interaction: advise patients to abstain from alcohol during and at least 48 hours after therapy to prevent disulfiram‑like reactions.
• Renal dysfunction: evaluate dosing in severe renal impairment and monitor renal parameters.
• Concomitant neurotoxic drugs: use caution with other agents that may increase risk of peripheral neuropathy.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Alcohol: can cause severe flushing, tachycardia, and hypotension (disulfiram‑like reaction).
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

• Lithium: potential for increased lithium levels; monitor serum concentrations.
• Cimetidine: may raise metronidazole plasma concentrations; observe for toxicity.
• Phenytoin: may reduce metronidazole levels, decreasing effectiveness.
• Phenobarbital: may increase metabolism of metronidazole, lowering its activity.